Scancell Share Discussion Threads

[bermudashorts] 06/11/2024 06:57

.......especially as SCIB1 was administered via electroporation for the 2018 paper, so maintaining that response rate shows that switching to PharmaJet needleless injection has not adversely affected performance.

[sci102] 06/11/2024 06:46

it's from a poster back in May

3 Paston, et al (2024). A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma. Cancer immunotherapy as Association (CIMT) 2024 poster.

however what I was thinking about was this paper from 2018, 88% back then. Good to see that the result is reproducible, as it is essentially the same. But, not new data.

[inanaco] 06/11/2024 06:30

with Drill baby Drill about to get elected it makes a mockery of Milibrain ...

talking of which we are stuck in zero wind ... the windmills have dropped to 3% output

Gas coal nuclear running full capacity and .... we are still having to import from Europe via the interconnectors

Germany in the same boat ... having shut its nukes

Good job its not seasonal cold !

Best close the North Sea Gas and Oil fields far better plan

[marcusl2] 05/11/2024 21:02

https

://pharmajet.com/pharmajet-poster-presentation-at-cancer-immunotherapy-conference-highlights-how-needle-free-technology-is-enhancing-oncology-solutions/

[sci102] 05/11/2024 19:31

this isn't new data. they shown specific t cell responses to at least one of the epitopes to be 87% at least a year ago. Again, guess who is the idiot.

[miavoce] 05/11/2024 19:20

If we have maintained 85% or above the results may only be a couple of weeks away....

[marcusl2] 05/11/2024 17:56

Data made public is creeping up, 87% now.


Bermuda
'Scancell: The Phase 2 trial with patients that have advanced unresectable melanoma who have received the SCIB1 or ISCIB1+ DNA vaccine with CPI, either with nivolumab and ipilimumab or pembrolizumab is ongoing. Latest data shows SCIB1 administered with Stratis has induced T cell responses in 87% of patients who have been given double CPI and showed a significant increase from baseline T cell counts with full cohort data still to be analyzed.3 According to Lindy Durrant, Scancell CEO, “To date, Stratis is the only technology which has shown effective uptake of the DNA vaccine through intramuscular delivery allowing native cellular machinery to express the target antigen and induce a potent anti-tumor response.”

https

://uk.advfn.com/cmn/fbb/edit_article.php3?id=53298080

[chilltime] 05/11/2024 17:49

DOM

He's not the messiah, he's a very naughty boy

[dominiccummings] 05/11/2024 17:01

You Sci102

[sci102] 05/11/2024 15:08

Technically the trial isn't complete until after the 2 years follow up of the last patient dosed. The last patient dosed and assessed for ORR per protocol is the primary completion, which is what we care about right now but it is not the full completion of the trial.

Guess who is really the idiot.

[chilltime] 05/11/2024 14:37

A reason why you should avoid analysts and do your own research

On an investment site this week.

a Master's degree in Investment Management


Yet this is what he said.

Based on current timelines, SCIB1 isn’t expected to complete Phase 2 trials until 2026.

Idiot.

[the real lozan] 05/11/2024 13:09

"Chief Supporter of Scancell" -
Chief Supporter of YOURSELF n YOUR EGO more like.
For genuine shareholders, YOU provide less 'support' than that of 'a tube in the center of a bog roll'

[inanaco] 05/11/2024 11:18

Chief Supporter of Scancell and Lindy Durrant

CSSLD ...

never had a bad word to say in 12 years !

instead had to listen to you moaning that its your worse investment ever

and constantly talking down your own investment

and worse year after year of it ....

a clear sign of insanity because you could have exited in profit on multiple occasions

[chilltime] 05/11/2024 11:15

I don’t think even the regular bulls here (you excluded Inan) fully appreciate the potential of the platforms here.

Keytruda was seen as a massive win for cancer and Merck along with various other PD1 type therapies.

Combinations now seen to be the growing trend for increased efficacy but for big pharma, BMS, Merck and various others, it can extend expiring patents (billions in revenue) by 10, 15 years or more. Combos are seen as patent extending, revenue security.

The Scancell vaccines Modi and Scib are groundbreaking in their ability to fight tumours in a monotherapy, in combinations, the gains in efficacy are looking substantial.

The only thing holding back a host of Scancell therapies, as a mono or combo is money.

A successful Scib data release phase 2 won’t just highlight Scib1 it will light the blue touch paper on the Scancell vaccine approach.

Not just promising pre clinical on the approach, but trial data way ahead of the standard of care.

TIGIT (immuno type therapy) became a hot topic with BMS paying $200m up front on a pre clinical candidate (2021). It gives an idea just how fired up a company can be over new approaches. The TIGIT route has failed for some. BMS abandoned theirs before results


Exciting times ahead, for Scancell

[gazza] 05/11/2024 11:01

Inan, "I am delighted to join Scancell at such an exciting juncture, "Wow, what as?

[inanaco] 05/11/2024 10:36

Interest rates ‘more likely’ to be cut after slowdown in services growth
The Bank of England is more likely to cut interest rates later this week after a closely watched survey showed Britain’s services sector grew at the slowest pace in 11 months, according to economists.

Thomas Pugh, economist at RSM UK, said the drop in the S&P Global UK Services PMI for October to 52 meant policymakers will reduce the Bank Rate from 5pc to 4.75pc on Thursday.

However, he warned that the tax rises announced in the Budget means borrowing costs will be kept on hold in December.

He said: “The big stimulus coming from the Budget, combined with higher employment costs, means inflation will be materially higher in 2025 and 2026, so a December rate cut now looks very unlikely.

“What’s more, we are now expecting four rate cuts next year, with the risk of fewer.”

Money markets indicate there is a 93pc chance of a rate cut on Thursday and a 28pc chance of another cut in December.

Traders expect interest rates to be reduced to nearly 4pc within a year.

telegraph

[inanaco] 05/11/2024 09:33

I am delighted to join Scancell at such an exciting juncture, with the company's complementary cancer vaccine platforms, ImmunoBody® and Moditope®, showing incredible potential in the clinic. Together with a dynamic and talented management team and Board of Directors,


patience

[inanaco] 05/11/2024 09:29

Fact is nobody knows on the outside what is going on in the inside ....

apart from all the indicators pointing to great results

to try and unpick that to give it value is impossible because its still sentiment driven

but targeting ORR at week 25 Gives us a very clear "hard Copy" picture of what is going on ... Ct or MRI

we do not have to wait for PFS to get an indication

and this applies to all three trials Modi1, Iscib1 and Scib1 using double checkpoint

but we also know that PFS is looking promising with Modi1 otherwise we would not have the rise from 40% to 60% SD will CTL-4 break the camel's back

dont forget its 4 indications that we can trial with this combination

this is why i have no idea yet of the scale of cash requirements

but each of the indications can become Block Busters in there own right

which of course will drive Modi2 into the clinic

all of a sudden we are 9 indications running

we know Modi3 is out there its being mentioned

I have no idea what goes on in Rucks Brain .... or if he actually understands the position we are potentially in ......


even thou Richard has told you many times . Moditope is a Land Grab patent

I am holding more than 1.6m not because of stupidity ....its because that basket of clinical investments beats holding multiple shares with the safety net of SCIB1 proven to work which means i can value it ... and its way more than the MCAP

I have never seen a market which has been dazzled by headlights ....

but if you do get your vision back ... its all about the number you hold

or just wear sunglasses like me ... 😎😎😎😎8526;😎ԅ26;😎

and they are not Rose Tinted ....

[marcusl2] 05/11/2024 08:32

This culminated in significant in vivo DMS79 tumor control in NOD/SCIDγ (NSG) mice, resulting in 30% OS that further increased in combination with the PDL1 inhibitor atezolizumab. Critically, SC134-TCB presented little evidence for off-tumor T-cell activation. The tumor-selective nature of FucGM1 expression combined with the functional antitumor attributes of SC134-TCB suggests potential as a FucGM1-targeted TCB therapy for SCLC.




Roche's Tecentriq (atezolizumab)

[gazza] 04/11/2024 22:33

Chilltime, Yes, I get all that they are all valid points and each one I have acknowledged in the past. The 100% dilution is my "worst case" scenario. This may well be reduced or even eliminated with a lower share price discount, milestone payments, up front deal for royalties or outright sale.

[chilltime] 04/11/2024 21:38

Just making a point Ruck

If Scancell raise money to run the trial that means a larger share of the market on success.

EG Trinity suggest 17.5% Royalties with a partner.

Funding doesn’t necessarily mean dilution. A partner could pay for the trial, various are interested talking to Scancell waiting for data.

Royalty type funding is becoming a trend.

They have cash coming from Glymab deals, how much we will see but the SCLC Glymab seems to have attracted material interest, probably due to it’s preclinical efficacy. and safety profile.

Even on a raise dilution I’d find it odd to have such discount on the back of such excellent data. They won’t be short of willing participants and have (going by Lindy’s comments) interested parties looking for decent stakes (an interview).

I think Scancell funding the trial alone is the least likely outcome.

It’s not just about Scib1, scib2 could do similar in combos for other cancers.

Scancell’s method is a largely overlooked approach and is proving to be highly effective.

[gazza] 04/11/2024 21:38

No it's not LOL

[inanaco] 04/11/2024 21:25

its you doing all the pointing .....

[ruckrover] 04/11/2024 21:17

Inan,"i guess he is no fool ....""showing incredible potential in the clinic""You are preaching to the converted. We all get the science, we all have seen the recruitment of a star studded board of directors, and the potential in the clinic. Most importantly, we all get the fact that vast amounts of money are required in order to reach that potential (including you)So what's your actual point?